|
Mikhaylenko E.V., Abdullaev Sh.P., Sychev D.A., Tchubarev V.N., Skripka A.I.
Pharmacoeconomic evaluation of genotype-guided dabigatran etexilate dosing in patients with atrial fibrillation and chronic kidney disease
|
№4 (приложение) / 2022
|
|
Nikulina S.Yu., Shishkova K.Yu., Chernova A.A., Schulman V.A.
Predicting the development of atrial fibrillation using multiple logistic regression
|
№9 / 2021
|
|
Roytberg G.E., Slastnikova I.D., Sharkhun O.O.
Management of elderly patients with nonvalvular atrial fibrillation: focus on «fragile» patients
|
№5 / 2021
|
|
Poteshkina N.G., Krylova N.S., Mikheeva L.V., Khadzegova A.B.
Anticoagulant therapy in case of atrial fibrillation for patients with chronic kidney disease
|
№3 / 2020
|
|
Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A., Rayimzhanov Z.R., Redjapova N.A., Yusupov F.A.
Braking progression of nephro- and cerebrovascular complications during atrial fibrillation: opportunities of rivaroxaban
|
№1 / 2020
|
|
Berns S.A., Pasechnik I.N., Golikova A.A., Talyzin P.A., Putilina M.V., Volkov A.K., Zverev K.V.
Oral direct anticoagulants: what to do with hemorrhagic complications?
|
№6 / 2019
|
|
Andriyanov M.T., Ilyicheva O.E.
The impact of risk factors of cardiovascular diseases development and progression on occurrence of paroxysmal atrial fibrillation in employable females
|
№4 / 2019
|
|
N.E. Agibova, O.I. Boeva
New possibilities for personalizing prognosis in patients with nonvalvular atrial fibrillation
|
№3 / 2018
|
|
I.S. Yavelov
Directly acting oral anticoagulants in the stroke prevention in patients with non-valvular atrial fibrillation and different concomitant diseases
|
№2 / 2017
|
|
A.V. Melekhov
Atrial fibrillation and chronic kidney disease: correction of treatment
|
№2 / 2017
|
|
V.V. Cheltsov, Yu.Sh. Guschina, Т.S. Illarionova, E.А. Korovyakova, А.I. Martynov
New possibilities of pharmacological cardioversion of newly developed paroxysm of atrial fibrillation
|
№3 / 2015
|
Русский
